Medical Condition News

RSS

Capsaicin may cause weight loss, fight fat buildup: Study

Capsaicin, the stuff that gives chili peppers their kick, may cause weight loss and fight fat buildup by triggering certain beneficial protein changes in the body, according to a new study on the topic. The report, which could lead to new treatments for obesity, appears in ACS' monthly Journal of Proteome Research.

22 Jul 2010

Study shows how muscle, fat could play role in survival of heart failure patients

University of Alberta research has discovered heart failure patients with more muscle have the potential to increase their length of life. Antigone Oreopoulos, a researcher from the U of A's School of Public Health, studied 140 patients with heart failure. Study participants underwent a special scan to measure their muscle mass and body fat.

22 Jul 2010

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

The Gladstone Institutes and the international pharmaceutical company H. Lundbeck A/S have announced a collaborative research agreement to study and identify therapeutic candidates for neurological diseases. The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD, and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging at the Gladstone Institute of Neurological Disease.

22 Jul 2010

New campaign empowers, inspires women and families affected by epilepsy

A new campaign explores the roles and responsibilities women uniquely encounter when living, or caring for a loved one, with epilepsy. "Women Succeeding with Epilepsy" is a collaboration between Epilepsy Advocate and HealthyWomen to educate, empower and inspire women and families whose lives are affected by epilepsy.

22 Jul 2010

SAIC-F selects SAIC-F selects Precision Antibody to provide characterization for reference antibody resource development

Precision Antibody announced today its selection by Science Applications International Corporation-Frederick to provide antibody and antigen characterization, including surface plasmon resonance analysis, for the National Cancer Institute's "Clinical Proteomic Technologies for Cancer" initiative. A goal of the CPTC is to develop a standardized resource of very high-quality, renewable reference antibodies generated against cancer-related proteins. The antibodies will be made available to proteomics researchers, along with characterization data and other information intended to support replication and standardization.

22 Jul 2010

Brain neuron activity can signal initiation, termination of behavioural sequences: Study

Rui Costa, Principal Investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciência, and Xin Jin, of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, describe in the latest issue of the journal Nature, that the activity of certain neurons in the brain can signal the initiation and termination of behavioural sequences we learn anew. Furthermore, they found that this brain activity is essential for learning and executing novel action sequences, many times compromised in patients suffering from disorders such as Parkinson's or Huntington's.

22 Jul 2010

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

22 Jul 2010

Medicare drug benefit appears to help more seniors with heart failure

The Medicare drug benefit may be helping more older Americans with heart failure get the medications recommended for controlling the disease, a new study finds. The study, of nearly 7,000 older heart failure patients in one large insurance plan, found that the number of filled prescriptions for standard heart failure medications increased after the Medicare drug benefit kicked in in 2006. The biggest increase was seen among seniors who had previously lacked any form of drug coverage.

22 Jul 2010

Survey links autism with digestive problems, intestinal inflammation

Autism is the fastest growing developmental disorder in the world. With 1 child in 91 facing the disorder, the diagnosis is more common than pediatric cancer, diabetes, and AIDS combined.

22 Jul 2010

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Caraco Pharmaceutical Laboratories, Ltd. has started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). These bupropion hydrochloride extended release tablets, 100 mg, 150 mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

22 Jul 2010

Womb cancer is the fourth most common cancer among UK women: Research

Womb cancer cases are highest ever for over three decades.The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

22 Jul 2010

Buffer among metbolism pathways induces cancer suppressing gene mutation: Research

Eighty years ago, the medical establishment believed cancer was caused by a dysfunction of metabolism, but the idea went out of vogue. Now, scientists are again looking at metabolism and its role in cancer and other common diseases. Metabolism is a highly connected network of reactions that are arranged in parallel and interacting pathways. Such parallelism can mask how genes are linked with disease traits and make it difficult to treat conditions.

22 Jul 2010

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Ampio Pharmaceuticals, Inc. today announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

22 Jul 2010

Surgery & physical therapy equally effective in knee ligament tears: study

A new study released this Wednesday compared intense physical therapy with surgery in common knee ligament injury and found that both techniques had similar outcomes.

21 Jul 2010

New findings suggest link between increased cholesterol, depression

Most people know that high cholesterol levels place them at increased risk for heart disease and stroke. Prior research has shown that particular types of strokes contribute to one's risk for depression, and that abnormal blood lipid levels can increase the risk of depression in the elderly.

21 Jul 2010

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

Tethys Bioscience, Inc., a privately held company, announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan. Participants in the venture financing included new investors Greenspring Associates, Inc. (formerly Montagu Newhall Associates, Inc.) and Paul Capital Investments, as well as current investors.

21 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the second quarter of 2010 were approximately DKK 73 million (approximately USD 12 million). Arzerra second quarter net sales in the U.S. and the rest of the world were approximately DKK 64 million (approximately USD 10.5 million) and approximately DKK 9 million (approximately USD 1.5 million) respectively.

21 Jul 2010

Medical Condition News

Capsaicin may cause weight loss, fight fat buildup: Study

Study shows how muscle, fat could play role in survival of heart failure patients

Gladstone Institutes, H. Lundbeck collaborate to identify therapeutic candidates for neurological diseases

New campaign empowers, inspires women and families affected by epilepsy

SAIC-F selects SAIC-F selects Precision Antibody to provide characterization for reference antibody resource development

Brain neuron activity can signal initiation, termination of behavioural sequences: Study

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Valproic acid halts vision loss in patients with retinitis pigmentosa

Medicare drug benefit appears to help more seniors with heart failure

Survey links autism with digestive problems, intestinal inflammation

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Womb cancer is the fourth most common cancer among UK women: Research

Buffer among metbolism pathways induces cancer suppressing gene mutation: Research

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Surgery & physical therapy equally effective in knee ligament tears: study

New findings suggest link between increased cholesterol, depression

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News